Core Points - Gongdong Medical (605369.SH) announced a share reduction by its shareholder, Jinch Investment, which sold 540,240 shares through centralized bidding from October 9 to October 30, 2025 [1] - Following this transaction, Jinch Investment and its concerted parties reduced their total shareholding from 141,558,049 shares to 141,017,809 shares, decreasing their ownership percentage from 64.21% to 63.96%, marking a change that touches the 1% threshold [1]

Core Viewpoint - Gongdong Medical announced a share reduction plan by its shareholder Taizhou Jinch Investment Management Partnership, which will not affect the company's control [1] Summary by Relevant Sections - **Share Reduction Details** - From October 9 to 30, 2025, Taizhou Jinch Investment Management Partnership will reduce its holdings by 540,240 shares through centralized bidding [1] - After this change, the total shares held by Jinch Investment and its concerted parties will decrease from 141,558,049 shares to 141,017,809 shares [1] - The shareholding percentage will drop from 64.21% to 63.96%, reaching a 1% threshold [1] - **Impact on Company Control** - The reduction is part of a planned divestment and does not trigger a mandatory takeover bid [1] - The company's controlling stake remains unaffected, and the reduction plan is not yet fully implemented [1]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][3][8] Financial Data - The third quarter financial report for 2025 was approved by the company's board of directors and audit committee, with no objections or abstentions [3] - The financial statements are unaudited, and the report period refers to the three months from the beginning to the end of the quarter [4][7] Non-Recurring Gains and Losses - The company has identified non-recurring gains and losses, but specific amounts and reasons for classification are not detailed in the provided documents [5] Shareholder Information - Information regarding the total number of common shareholders and the top ten shareholders is mentioned, but specific details are not provided in the documents [6]

Group 1 - The core viewpoint of the news is that Gongdong Medical reported its third-quarter performance, showing a slight increase in revenue but a significant decrease in net profit [1] Group 2 - Gongdong Medical's revenue for the first three quarters of 2025 is approximately 845 million yuan, representing a year-on-year increase of 1.08% [1] - The net profit attributable to shareholders of the listed company is approximately 71.96 million yuan, reflecting a year-on-year decrease of 49.1% [1] - As of the report date, Gongdong Medical's market capitalization is 4.2 billion yuan [2]

Core Viewpoint - Gongdong Medical (605369.SH) reported a total operating revenue of 845 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 1.08% [1] - The net profit attributable to shareholders decreased by 49.1% to 71.96 million yuan, with basic earnings per share at 0.33 yuan [1] Financial Performance - Total operating revenue for the first three quarters reached 845 million yuan, showing a slight increase of 1.08% compared to the previous year [1] - Net profit attributable to the parent company's shareholders was 71.96 million yuan, marking a significant decline of 49.1% year-on-year [1] - Basic earnings per share stood at 0.33 yuan [1]

Financial Performance - The company's operating revenue for the third quarter was CNY 288,161,548.30, representing a year-on-year increase of 2.07%[5] - The total profit for the quarter was CNY 23,240,171.71, showing a significant decrease of 54.42% compared to the same period last year[6] - The net profit attributable to shareholders was CNY 21,615,278.21, down 53.12% year-on-year[6] - The basic earnings per share for the quarter was CNY 0.10, a decrease of 52.38% compared to the previous year[6] - The company experienced a 49.97% decline in total profit for the year-to-date compared to the same period last year[10] - Net profit for the first three quarters of 2025 was ¥71,890,298.22, down from ¥141,382,840.75 in 2024, indicating a decline of approximately 49.1%[22] - The company experienced a decrease in total comprehensive income to ¥66,810,834.59 from ¥135,771,968.77, a decline of approximately 50.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,127,116,445.47, an increase of 9.01% from the end of the previous year[6] - Current assets as of September 30, 2025, totaled RMB 1,102,686,133.56, up from RMB 865,266,163.55 at the end of 2024, indicating a significant increase in liquidity[16] - Total liabilities as of September 30, 2025, amounted to RMB 393,205,904.63, compared to RMB 233,788,763.79 at the end of 2024, indicating a significant rise in financial obligations[18] - The company's total assets reached RMB 2,127,116,445.47, up from RMB 1,951,340,242.04, reflecting a growth of approximately 9%[18] - Non-current assets decreased to RMB 1,024,430,311.91 from RMB 1,086,074,078.49, indicating a decline of about 5.7%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 149,044,625.16, reflecting a 2.38% increase[6] - The net cash flow from operating activities was ¥149,044,625.16, compared to ¥145,584,021.87 in the previous year, showing a slight increase of about 3.18%[26] - Cash and cash equivalents increased to RMB 507,913,240.40 from RMB 303,188,874.77, reflecting a growth of approximately 67.5%[16] - Cash and cash equivalents at the end of the period totaled ¥507,913,240.40, up from ¥502,874,015.62 at the end of the same period last year, reflecting a growth of approximately 1.04%[27] - The company reported a net cash outflow from investing activities of ¥42,246,685.27, compared to a net outflow of ¥30,209,819.55 in the previous year, indicating an increase in investment expenditures[27] - Cash inflow from financing activities was ¥247,132,128.00, significantly higher than ¥70,500,000.00 in the same period of 2024, representing an increase of approximately 250.5%[27] Shareholder Information - The company has a total of 11,604 common shareholders at the end of the reporting period[12] - The company reported a total of 10 major shareholders, with the largest holding 110,836,040 shares, representing a significant concentration of ownership[14] Operating Costs - Total operating costs increased to ¥752,127,483.02 from ¥683,540,594.88, marking a rise of about 10.05% year-over-year[22] Tax Expenses - The company’s tax expenses for the period were ¥7,204,990.44, down from ¥16,726,505.45 in the previous year, indicating a decrease of about 56.9%[22]

Core Viewpoint - The stock of Gongdong Medical has experienced a decline in price and trading volume, with a current market capitalization of 4.187 billion yuan, reflecting a challenging market environment for the company [1]. Company Overview - Gongdong Medical, established on August 17, 2009, and listed on September 16, 2020, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of disposable medical consumables [1]. - The revenue composition of Gongdong Medical includes: medical testing (39.95%), blood collection (27.43%), collection (11.18%), medical care (9.17%), others (4.94%), pharmaceutical packaging (3.73%), and commercial (3.60%) [1]. Financial Performance - For the first half of 2025, Gongdong Medical reported a revenue of 557 million yuan, representing a year-on-year growth of 0.58%. However, the net profit attributable to shareholders decreased by 47.16% to 50.349 million yuan [2]. - Since its A-share listing, Gongdong Medical has distributed a total of 533 million yuan in dividends, with 234 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Gongdong Medical increased to 9,870, up by 10.79% from the previous period. The average number of circulating shares per person rose by 26.30% to 22,339 shares [2]. - Notably, Industrial and Commercial Bank of China Medical Health Stock (000831) has exited the list of the top ten circulating shareholders [3].

Core Points - The stock price of Gongdong Medical (605369) increased by 2.37% this week, closing at 19.44 yuan as of October 10, 2025, with a market cap of 4.286 billion yuan [1] - The company revised its articles of association, confirming its status as a permanent company with a registered capital of 220,492,949 yuan [2] Company Announcements - Gongdong Medical's articles of association state that it is a permanent limited company with a registered capital of 220,492,949 yuan, focusing on the production and operation of Class III medical devices [2] - The company has established a shareholder meeting, board of directors, and supervisory board, outlining the rights and obligations of shareholders, directors, and senior management [2] - Directors and senior management are prohibited from insider trading, and any short-term trading profits by shareholders holding over 5% of shares must be returned to the company [2] - The profit distribution policy emphasizes cash dividends, with a minimum of 10% of distributable profits to be distributed annually [2] - Major transactions and external guarantees require approval from the board or shareholders' meeting [2] - The company is allowed to repurchase shares for employee incentives or capital reduction, with a maximum repurchase limit of 10% of the total issued shares [2] - The articles also regulate the procedures for shareholder meetings, board meetings, mergers, divisions, dissolution, and liquidation [2]

浙江拱东医疗器械股份有限公司 章 程 二零二五年九月 目 录 第三章 股 份 第四章 股东和股东会 第五章 董事和董事会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 第八章 通知和公告 第十一章 附 则 1 第一章 总 则 第二章 经营宗旨和范围 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第一节 通 知 第二节 公 告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 浙江拱东医疗器械股份有限公司 章 程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益,规范公司的组织和行 为,根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2025-034 公司已于近日完成《公司章程》的工商备案手续，经工商登记机关审核并备 案的《公司章程》详见与本公告同日披露的《公司章程（2025 年 9 月）》。 特此公告。 浙江拱东医疗器械股份有限公司董事会 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 | | --- | | 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 浙江拱东医疗器械股份有限公司（以下简称"公司"）于 2025 年 9 月 18 日 召开公司 2025 年第一次临时股东大会，审议通过了《关于取消监事会并修订〈公 司章程〉的议案》等议案，公司对《公司章程》进行了相应修订，《公司章程》 修订的具体内容敬请查阅公司 2025 年 8 月 26 日披露于上海证券交易所网站 （www.sse.com.cn）的《关于取消监事会并修订〈公司章程〉及制定、修订部分 管理制度的公告》（公告编号：2025-027）。 浙江拱东医疗器械股份有限公司 关于完成《公司章程》备案的公告 2025 年 10 月 10 日 ...